nodes	percent_of_prediction	percent_of_DWPC	metapath
Nilotinib—CA1—glaucoma	0.155	0.569	CbGaD
Nilotinib—CA2—glaucoma	0.117	0.431	CbGaD
Nilotinib—CA3—Acetazolamide—glaucoma	0.0274	0.0548	CbGbCtD
Nilotinib—CA14—Brinzolamide—glaucoma	0.0165	0.0331	CbGbCtD
Nilotinib—CA14—Diclofenamide—glaucoma	0.0165	0.0331	CbGbCtD
Nilotinib—CA14—Dorzolamide—glaucoma	0.0159	0.0319	CbGbCtD
Nilotinib—CA6—Diclofenamide—glaucoma	0.0157	0.0314	CbGbCtD
Nilotinib—CA6—Brinzolamide—glaucoma	0.0157	0.0314	CbGbCtD
Nilotinib—CA6—Dorzolamide—glaucoma	0.0151	0.0303	CbGbCtD
Nilotinib—CA14—Methazolamide—glaucoma	0.0142	0.0285	CbGbCtD
Nilotinib—CA7—Diclofenamide—glaucoma	0.0137	0.0274	CbGbCtD
Nilotinib—CA7—Brinzolamide—glaucoma	0.0137	0.0274	CbGbCtD
Nilotinib—CA6—Methazolamide—glaucoma	0.0135	0.027	CbGbCtD
Nilotinib—CA7—Dorzolamide—glaucoma	0.0132	0.0264	CbGbCtD
Nilotinib—CA7—Methazolamide—glaucoma	0.0118	0.0236	CbGbCtD
Nilotinib—CA9—Brinzolamide—glaucoma	0.0117	0.0235	CbGbCtD
Nilotinib—CA12—Brinzolamide—glaucoma	0.0117	0.0235	CbGbCtD
Nilotinib—CA12—Diclofenamide—glaucoma	0.0117	0.0235	CbGbCtD
Nilotinib—CA9—Diclofenamide—glaucoma	0.0117	0.0235	CbGbCtD
Nilotinib—CA14—Acetazolamide—glaucoma	0.0114	0.0228	CbGbCtD
Nilotinib—CA12—Dorzolamide—glaucoma	0.0113	0.0227	CbGbCtD
Nilotinib—CA9—Dorzolamide—glaucoma	0.0113	0.0227	CbGbCtD
Nilotinib—CA1—Diclofenamide—glaucoma	0.011	0.022	CbGbCtD
Nilotinib—CA1—Brinzolamide—glaucoma	0.011	0.022	CbGbCtD
Nilotinib—CA6—Acetazolamide—glaucoma	0.0108	0.0216	CbGbCtD
Nilotinib—CA1—Dorzolamide—glaucoma	0.0106	0.0212	CbGbCtD
Nilotinib—CA4—Brinzolamide—glaucoma	0.0103	0.0207	CbGbCtD
Nilotinib—CA4—Diclofenamide—glaucoma	0.0103	0.0207	CbGbCtD
Nilotinib—CA9—Methazolamide—glaucoma	0.0101	0.0202	CbGbCtD
Nilotinib—CA12—Methazolamide—glaucoma	0.0101	0.0202	CbGbCtD
Nilotinib—CA4—Dorzolamide—glaucoma	0.00996	0.02	CbGbCtD
Nilotinib—CA2—Diclofenamide—glaucoma	0.00948	0.019	CbGbCtD
Nilotinib—CA2—Brinzolamide—glaucoma	0.00948	0.019	CbGbCtD
Nilotinib—CA1—Methazolamide—glaucoma	0.00945	0.0189	CbGbCtD
Nilotinib—CA7—Acetazolamide—glaucoma	0.0094	0.0188	CbGbCtD
Nilotinib—CA2—Dorzolamide—glaucoma	0.00916	0.0183	CbGbCtD
Nilotinib—CA4—Methazolamide—glaucoma	0.00888	0.0178	CbGbCtD
Nilotinib—CA2—Methazolamide—glaucoma	0.00816	0.0164	CbGbCtD
Nilotinib—CA9—Acetazolamide—glaucoma	0.00807	0.0162	CbGbCtD
Nilotinib—CA12—Acetazolamide—glaucoma	0.00807	0.0162	CbGbCtD
Nilotinib—CA1—Acetazolamide—glaucoma	0.00755	0.0151	CbGbCtD
Nilotinib—CA4—Acetazolamide—glaucoma	0.0071	0.0142	CbGbCtD
Nilotinib—CA2—Acetazolamide—glaucoma	0.00653	0.0131	CbGbCtD
Nilotinib—CYP2D6—Carteolol—glaucoma	0.00258	0.00516	CbGbCtD
Nilotinib—CYP2D6—Betaxolol—glaucoma	0.00174	0.00349	CbGbCtD
Nilotinib—CYP2C9—Diclofenamide—glaucoma	0.00168	0.00336	CbGbCtD
Nilotinib—CYP2C9—Dorzolamide—glaucoma	0.00162	0.00324	CbGbCtD
Nilotinib—MAPK8—endothelium—glaucoma	0.00151	0.0761	CbGeAlD
Nilotinib—CYP2C9—Methazolamide—glaucoma	0.00144	0.00289	CbGbCtD
Nilotinib—CYP2D6—Methazolamide—glaucoma	0.00132	0.00264	CbGbCtD
Nilotinib—TIE1—endothelium—glaucoma	0.00131	0.066	CbGeAlD
Nilotinib—CYP3A4—Pilocarpine—glaucoma	0.00124	0.00249	CbGbCtD
Nilotinib—ABCB1—Timolol—glaucoma	0.00119	0.00238	CbGbCtD
Nilotinib—CYP2D6—Timolol—glaucoma	0.00112	0.00225	CbGbCtD
Nilotinib—Imatinib—NTRK1—glaucoma	0.00102	0.451	CrCbGaD
Nilotinib—ABCB1—Clonidine—glaucoma	0.00101	0.00203	CbGbCtD
Nilotinib—CYP3A4—Brinzolamide—glaucoma	0.000974	0.00195	CbGbCtD
Nilotinib—CYP2D6—Clonidine—glaucoma	0.000953	0.00191	CbGbCtD
Nilotinib—CYP3A4—Dorzolamide—glaucoma	0.000941	0.00188	CbGbCtD
Nilotinib—EPHB2—retina—glaucoma	0.000916	0.0463	CbGeAlD
Nilotinib—EPHB4—endothelium—glaucoma	0.000907	0.0458	CbGeAlD
Nilotinib—EPHA8—eye—glaucoma	0.000886	0.0448	CbGeAlD
Nilotinib—TEK—endothelium—glaucoma	0.000868	0.0438	CbGeAlD
Nilotinib—CYP3A4—Methazolamide—glaucoma	0.000838	0.00168	CbGbCtD
Nilotinib—CDC42BPB—eye—glaucoma	0.000817	0.0413	CbGeAlD
Nilotinib—CDC42BPB—retina—glaucoma	0.00081	0.0409	CbGeAlD
Nilotinib—EPHA3—eye—glaucoma	0.000775	0.0391	CbGeAlD
Nilotinib—EPHA3—retina—glaucoma	0.000768	0.0388	CbGeAlD
Nilotinib—MAPK8—eye—glaucoma	0.000739	0.0373	CbGeAlD
Nilotinib—MAPK8—retina—glaucoma	0.000733	0.037	CbGeAlD
Nilotinib—MAPK8—connective tissue—glaucoma	0.000712	0.036	CbGeAlD
Nilotinib—Imatinib—CA1—glaucoma	0.00071	0.312	CrCbGaD
Nilotinib—CYP3A4—Acetazolamide—glaucoma	0.00067	0.00134	CbGbCtD
Nilotinib—MAP4K1—retina—glaucoma	0.000666	0.0336	CbGeAlD
Nilotinib—LYN—connective tissue—glaucoma	0.000657	0.0332	CbGeAlD
Nilotinib—KIT—endothelium—glaucoma	0.000629	0.0318	CbGeAlD
Nilotinib—CYP3A4—Clonidine—glaucoma	0.000606	0.00121	CbGbCtD
Nilotinib—Imatinib—CA2—glaucoma	0.000538	0.237	CrCbGaD
Nilotinib—CA3—connective tissue—glaucoma	0.000485	0.0245	CbGeAlD
Nilotinib—MAPK14—connective tissue—glaucoma	0.000452	0.0228	CbGeAlD
Nilotinib—EPHB4—connective tissue—glaucoma	0.000429	0.0217	CbGeAlD
Nilotinib—TEK—connective tissue—glaucoma	0.00041	0.0207	CbGeAlD
Nilotinib—PDGFRA—connective tissue—glaucoma	0.000372	0.0188	CbGeAlD
Nilotinib—CA12—eye—glaucoma	0.000356	0.018	CbGeAlD
Nilotinib—CA12—connective tissue—glaucoma	0.000343	0.0173	CbGeAlD
Nilotinib—CSF1R—eye—glaucoma	0.00034	0.0172	CbGeAlD
Nilotinib—CSF1R—connective tissue—glaucoma	0.000327	0.0165	CbGeAlD
Nilotinib—PDGFRB—eye—glaucoma	0.000301	0.0152	CbGeAlD
Nilotinib—KIT—connective tissue—glaucoma	0.000297	0.015	CbGeAlD
Nilotinib—PDGFRB—connective tissue—glaucoma	0.00029	0.0147	CbGeAlD
Nilotinib—CA1—eye—glaucoma	0.000282	0.0143	CbGeAlD
Nilotinib—ABL1—eye—glaucoma	0.000269	0.0136	CbGeAlD
Nilotinib—ABL1—retina—glaucoma	0.000266	0.0134	CbGeAlD
Nilotinib—ABL1—connective tissue—glaucoma	0.000259	0.0131	CbGeAlD
Nilotinib—CA2—eye—glaucoma	0.000183	0.00924	CbGeAlD
Nilotinib—CA2—retina—glaucoma	0.000181	0.00915	CbGeAlD
Nilotinib—CA2—connective tissue—glaucoma	0.000176	0.0089	CbGeAlD
Nilotinib—ABCB1—retina—glaucoma	8.28e-05	0.00418	CbGeAlD
Nilotinib—Syncope—Clonidine—glaucoma	4.42e-05	0.00039	CcSEcCtD
Nilotinib—Arrhythmia—Betaxolol—glaucoma	4.41e-05	0.000389	CcSEcCtD
Nilotinib—Feeling abnormal—Dorzolamide—glaucoma	4.39e-05	0.000388	CcSEcCtD
Nilotinib—Decreased appetite—Pilocarpine—glaucoma	4.38e-05	0.000387	CcSEcCtD
Nilotinib—Feeling abnormal—Travoprost—glaucoma	4.38e-05	0.000386	CcSEcCtD
Nilotinib—Conjunctivitis—Timolol—glaucoma	4.36e-05	0.000385	CcSEcCtD
Nilotinib—Gastrointestinal pain—Dorzolamide—glaucoma	4.36e-05	0.000385	CcSEcCtD
Nilotinib—Alopecia—Betaxolol—glaucoma	4.36e-05	0.000385	CcSEcCtD
Nilotinib—Palpitations—Clonidine—glaucoma	4.36e-05	0.000385	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Pilocarpine—glaucoma	4.35e-05	0.000384	CcSEcCtD
Nilotinib—Gastrointestinal pain—Travoprost—glaucoma	4.34e-05	0.000383	CcSEcCtD
Nilotinib—Loss of consciousness—Clonidine—glaucoma	4.33e-05	0.000383	CcSEcCtD
Nilotinib—Feeling abnormal—Brinzolamide—glaucoma	4.32e-05	0.000382	CcSEcCtD
Nilotinib—Mental disorder—Betaxolol—glaucoma	4.32e-05	0.000382	CcSEcCtD
Nilotinib—Pain—Pilocarpine—glaucoma	4.31e-05	0.000381	CcSEcCtD
Nilotinib—Constipation—Pilocarpine—glaucoma	4.31e-05	0.000381	CcSEcCtD
Nilotinib—Cough—Clonidine—glaucoma	4.3e-05	0.00038	CcSEcCtD
Nilotinib—Dizziness—Apraclonidine—glaucoma	4.3e-05	0.00038	CcSEcCtD
Nilotinib—Malnutrition—Betaxolol—glaucoma	4.29e-05	0.000379	CcSEcCtD
Nilotinib—Erythema—Betaxolol—glaucoma	4.29e-05	0.000379	CcSEcCtD
Nilotinib—Urticaria—Dorzolamide—glaucoma	4.24e-05	0.000374	CcSEcCtD
Nilotinib—Epistaxis—Timolol—glaucoma	4.23e-05	0.000374	CcSEcCtD
Nilotinib—Abdominal pain—Dorzolamide—glaucoma	4.22e-05	0.000372	CcSEcCtD
Nilotinib—Body temperature increased—Dorzolamide—glaucoma	4.22e-05	0.000372	CcSEcCtD
Nilotinib—Dysgeusia—Betaxolol—glaucoma	4.2e-05	0.000371	CcSEcCtD
Nilotinib—Arthralgia—Clonidine—glaucoma	4.2e-05	0.000371	CcSEcCtD
Nilotinib—Chest pain—Clonidine—glaucoma	4.2e-05	0.000371	CcSEcCtD
Nilotinib—Abdominal pain—Travoprost—glaucoma	4.2e-05	0.000371	CcSEcCtD
Nilotinib—Anxiety—Clonidine—glaucoma	4.18e-05	0.000369	CcSEcCtD
Nilotinib—Asthenia—Acetazolamide—glaucoma	4.17e-05	0.000369	CcSEcCtD
Nilotinib—Dizziness—Bimatoprost—glaucoma	4.17e-05	0.000368	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Clonidine—glaucoma	4.17e-05	0.000368	CcSEcCtD
Nilotinib—Urticaria—Brinzolamide—glaucoma	4.17e-05	0.000368	CcSEcCtD
Nilotinib—Feeling abnormal—Pilocarpine—glaucoma	4.15e-05	0.000367	CcSEcCtD
Nilotinib—Discomfort—Clonidine—glaucoma	4.15e-05	0.000366	CcSEcCtD
Nilotinib—Vomiting—Apraclonidine—glaucoma	4.14e-05	0.000365	CcSEcCtD
Nilotinib—Muscle spasms—Betaxolol—glaucoma	4.13e-05	0.000364	CcSEcCtD
Nilotinib—Gastrointestinal pain—Pilocarpine—glaucoma	4.12e-05	0.000364	CcSEcCtD
Nilotinib—Hypersensitivity—Brimonidine—glaucoma	4.11e-05	0.000363	CcSEcCtD
Nilotinib—Dry mouth—Clonidine—glaucoma	4.11e-05	0.000363	CcSEcCtD
Nilotinib—Bradycardia—Timolol—glaucoma	4.1e-05	0.000362	CcSEcCtD
Nilotinib—Dermatitis—Apraclonidine—glaucoma	4.1e-05	0.000362	CcSEcCtD
Nilotinib—Headache—Apraclonidine—glaucoma	4.08e-05	0.00036	CcSEcCtD
Nilotinib—Confusional state—Clonidine—glaucoma	4.06e-05	0.000358	CcSEcCtD
Nilotinib—Vision blurred—Betaxolol—glaucoma	4.05e-05	0.000357	CcSEcCtD
Nilotinib—Rhinitis—Timolol—glaucoma	4.04e-05	0.000357	CcSEcCtD
Nilotinib—Oedema—Clonidine—glaucoma	4.02e-05	0.000355	CcSEcCtD
Nilotinib—Tremor—Betaxolol—glaucoma	4.02e-05	0.000355	CcSEcCtD
Nilotinib—Asthenia—Brimonidine—glaucoma	4.01e-05	0.000354	CcSEcCtD
Nilotinib—Infection—Clonidine—glaucoma	4e-05	0.000353	CcSEcCtD
Nilotinib—Body temperature increased—Pilocarpine—glaucoma	3.98e-05	0.000352	CcSEcCtD
Nilotinib—Abdominal pain—Pilocarpine—glaucoma	3.98e-05	0.000352	CcSEcCtD
Nilotinib—Ill-defined disorder—Betaxolol—glaucoma	3.98e-05	0.000352	CcSEcCtD
Nilotinib—Diarrhoea—Acetazolamide—glaucoma	3.98e-05	0.000352	CcSEcCtD
Nilotinib—Rash—Bimatoprost—glaucoma	3.98e-05	0.000351	CcSEcCtD
Nilotinib—Dermatitis—Bimatoprost—glaucoma	3.97e-05	0.000351	CcSEcCtD
Nilotinib—Oedema peripheral—Timolol—glaucoma	3.97e-05	0.00035	CcSEcCtD
Nilotinib—Anaemia—Betaxolol—glaucoma	3.97e-05	0.00035	CcSEcCtD
Nilotinib—Shock—Clonidine—glaucoma	3.96e-05	0.00035	CcSEcCtD
Nilotinib—Connective tissue disorder—Timolol—glaucoma	3.96e-05	0.00035	CcSEcCtD
Nilotinib—Pruritus—Brimonidine—glaucoma	3.95e-05	0.000349	CcSEcCtD
Nilotinib—Headache—Bimatoprost—glaucoma	3.95e-05	0.000349	CcSEcCtD
Nilotinib—Nervous system disorder—Clonidine—glaucoma	3.95e-05	0.000349	CcSEcCtD
Nilotinib—Thrombocytopenia—Clonidine—glaucoma	3.94e-05	0.000348	CcSEcCtD
Nilotinib—Hypersensitivity—Dorzolamide—glaucoma	3.93e-05	0.000347	CcSEcCtD
Nilotinib—Tachycardia—Clonidine—glaucoma	3.93e-05	0.000347	CcSEcCtD
Nilotinib—Hypersensitivity—Travoprost—glaucoma	3.91e-05	0.000345	CcSEcCtD
Nilotinib—Skin disorder—Clonidine—glaucoma	3.91e-05	0.000345	CcSEcCtD
Nilotinib—Hyperhidrosis—Clonidine—glaucoma	3.89e-05	0.000344	CcSEcCtD
Nilotinib—Visual impairment—Timolol—glaucoma	3.88e-05	0.000343	CcSEcCtD
Nilotinib—Malaise—Betaxolol—glaucoma	3.87e-05	0.000342	CcSEcCtD
Nilotinib—Nausea—Apraclonidine—glaucoma	3.86e-05	0.000341	CcSEcCtD
Nilotinib—Hypersensitivity—Brinzolamide—glaucoma	3.86e-05	0.000341	CcSEcCtD
Nilotinib—Vertigo—Betaxolol—glaucoma	3.86e-05	0.000341	CcSEcCtD
Nilotinib—Syncope—Betaxolol—glaucoma	3.85e-05	0.00034	CcSEcCtD
Nilotinib—Dizziness—Acetazolamide—glaucoma	3.85e-05	0.00034	CcSEcCtD
Nilotinib—Anorexia—Clonidine—glaucoma	3.84e-05	0.000339	CcSEcCtD
Nilotinib—Asthenia—Dorzolamide—glaucoma	3.83e-05	0.000338	CcSEcCtD
Nilotinib—Asthenia—Travoprost—glaucoma	3.81e-05	0.000336	CcSEcCtD
Nilotinib—Palpitations—Betaxolol—glaucoma	3.79e-05	0.000335	CcSEcCtD
Nilotinib—Pruritus—Dorzolamide—glaucoma	3.77e-05	0.000333	CcSEcCtD
Nilotinib—Loss of consciousness—Betaxolol—glaucoma	3.77e-05	0.000333	CcSEcCtD
Nilotinib—Eye disorder—Timolol—glaucoma	3.77e-05	0.000332	CcSEcCtD
Nilotinib—Asthenia—Brinzolamide—glaucoma	3.76e-05	0.000332	CcSEcCtD
Nilotinib—Hypotension—Clonidine—glaucoma	3.76e-05	0.000332	CcSEcCtD
Nilotinib—Pruritus—Travoprost—glaucoma	3.76e-05	0.000332	CcSEcCtD
Nilotinib—Tinnitus—Timolol—glaucoma	3.76e-05	0.000332	CcSEcCtD
Nilotinib—Cough—Betaxolol—glaucoma	3.75e-05	0.000331	CcSEcCtD
Nilotinib—Nausea—Bimatoprost—glaucoma	3.75e-05	0.000331	CcSEcCtD
Nilotinib—Cardiac disorder—Timolol—glaucoma	3.74e-05	0.00033	CcSEcCtD
Nilotinib—Hypersensitivity—Pilocarpine—glaucoma	3.71e-05	0.000328	CcSEcCtD
Nilotinib—Pruritus—Brinzolamide—glaucoma	3.71e-05	0.000328	CcSEcCtD
Nilotinib—Vomiting—Acetazolamide—glaucoma	3.7e-05	0.000327	CcSEcCtD
Nilotinib—Dizziness—Brimonidine—glaucoma	3.69e-05	0.000326	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Clonidine—glaucoma	3.67e-05	0.000324	CcSEcCtD
Nilotinib—Angiopathy—Timolol—glaucoma	3.66e-05	0.000323	CcSEcCtD
Nilotinib—Myalgia—Betaxolol—glaucoma	3.65e-05	0.000323	CcSEcCtD
Nilotinib—Arthralgia—Betaxolol—glaucoma	3.65e-05	0.000323	CcSEcCtD
Nilotinib—Chest pain—Betaxolol—glaucoma	3.65e-05	0.000323	CcSEcCtD
Nilotinib—Diarrhoea—Dorzolamide—glaucoma	3.65e-05	0.000322	CcSEcCtD
Nilotinib—Headache—Acetazolamide—glaucoma	3.65e-05	0.000322	CcSEcCtD
Nilotinib—Anxiety—Betaxolol—glaucoma	3.64e-05	0.000322	CcSEcCtD
Nilotinib—Insomnia—Clonidine—glaucoma	3.64e-05	0.000321	CcSEcCtD
Nilotinib—Immune system disorder—Timolol—glaucoma	3.64e-05	0.000321	CcSEcCtD
Nilotinib—Diarrhoea—Travoprost—glaucoma	3.63e-05	0.000321	CcSEcCtD
Nilotinib—Mediastinal disorder—Timolol—glaucoma	3.63e-05	0.000321	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Betaxolol—glaucoma	3.63e-05	0.000321	CcSEcCtD
Nilotinib—Asthenia—Pilocarpine—glaucoma	3.62e-05	0.000319	CcSEcCtD
Nilotinib—Paraesthesia—Clonidine—glaucoma	3.61e-05	0.000319	CcSEcCtD
Nilotinib—Discomfort—Betaxolol—glaucoma	3.61e-05	0.000319	CcSEcCtD
Nilotinib—Arrhythmia—Timolol—glaucoma	3.6e-05	0.000318	CcSEcCtD
Nilotinib—Dyspnoea—Clonidine—glaucoma	3.59e-05	0.000317	CcSEcCtD
Nilotinib—Diarrhoea—Brinzolamide—glaucoma	3.59e-05	0.000317	CcSEcCtD
Nilotinib—Dry mouth—Betaxolol—glaucoma	3.57e-05	0.000316	CcSEcCtD
Nilotinib—Pruritus—Pilocarpine—glaucoma	3.57e-05	0.000315	CcSEcCtD
Nilotinib—Alopecia—Timolol—glaucoma	3.56e-05	0.000314	CcSEcCtD
Nilotinib—Confusional state—Betaxolol—glaucoma	3.53e-05	0.000312	CcSEcCtD
Nilotinib—Mental disorder—Timolol—glaucoma	3.53e-05	0.000312	CcSEcCtD
Nilotinib—Dizziness—Dorzolamide—glaucoma	3.53e-05	0.000311	CcSEcCtD
Nilotinib—Rash—Brimonidine—glaucoma	3.52e-05	0.000311	CcSEcCtD
Nilotinib—Dermatitis—Brimonidine—glaucoma	3.52e-05	0.000311	CcSEcCtD
Nilotinib—Dizziness—Travoprost—glaucoma	3.51e-05	0.00031	CcSEcCtD
Nilotinib—Malnutrition—Timolol—glaucoma	3.51e-05	0.00031	CcSEcCtD
Nilotinib—Erythema—Timolol—glaucoma	3.51e-05	0.00031	CcSEcCtD
Nilotinib—Oedema—Betaxolol—glaucoma	3.5e-05	0.000309	CcSEcCtD
Nilotinib—Headache—Brimonidine—glaucoma	3.5e-05	0.000309	CcSEcCtD
Nilotinib—Decreased appetite—Clonidine—glaucoma	3.5e-05	0.000309	CcSEcCtD
Nilotinib—Infection—Betaxolol—glaucoma	3.48e-05	0.000307	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Clonidine—glaucoma	3.47e-05	0.000307	CcSEcCtD
Nilotinib—Fatigue—Clonidine—glaucoma	3.47e-05	0.000306	CcSEcCtD
Nilotinib—Dizziness—Brinzolamide—glaucoma	3.47e-05	0.000306	CcSEcCtD
Nilotinib—Nausea—Acetazolamide—glaucoma	3.46e-05	0.000305	CcSEcCtD
Nilotinib—Diarrhoea—Pilocarpine—glaucoma	3.45e-05	0.000304	CcSEcCtD
Nilotinib—Shock—Betaxolol—glaucoma	3.45e-05	0.000304	CcSEcCtD
Nilotinib—Constipation—Clonidine—glaucoma	3.44e-05	0.000304	CcSEcCtD
Nilotinib—Pain—Clonidine—glaucoma	3.44e-05	0.000304	CcSEcCtD
Nilotinib—Nervous system disorder—Betaxolol—glaucoma	3.44e-05	0.000303	CcSEcCtD
Nilotinib—Dysgeusia—Timolol—glaucoma	3.43e-05	0.000303	CcSEcCtD
Nilotinib—Thrombocytopenia—Betaxolol—glaucoma	3.43e-05	0.000303	CcSEcCtD
Nilotinib—Tachycardia—Betaxolol—glaucoma	3.42e-05	0.000302	CcSEcCtD
Nilotinib—Skin disorder—Betaxolol—glaucoma	3.4e-05	0.000301	CcSEcCtD
Nilotinib—Vomiting—Dorzolamide—glaucoma	3.39e-05	0.000299	CcSEcCtD
Nilotinib—Hyperhidrosis—Betaxolol—glaucoma	3.39e-05	0.000299	CcSEcCtD
Nilotinib—Rash—Dorzolamide—glaucoma	3.36e-05	0.000297	CcSEcCtD
Nilotinib—Dermatitis—Dorzolamide—glaucoma	3.36e-05	0.000297	CcSEcCtD
Nilotinib—Rash—Travoprost—glaucoma	3.35e-05	0.000296	CcSEcCtD
Nilotinib—Dermatitis—Travoprost—glaucoma	3.35e-05	0.000295	CcSEcCtD
Nilotinib—Headache—Dorzolamide—glaucoma	3.34e-05	0.000295	CcSEcCtD
Nilotinib—Anorexia—Betaxolol—glaucoma	3.34e-05	0.000295	CcSEcCtD
Nilotinib—Vomiting—Brinzolamide—glaucoma	3.33e-05	0.000294	CcSEcCtD
Nilotinib—Dizziness—Pilocarpine—glaucoma	3.33e-05	0.000294	CcSEcCtD
Nilotinib—Headache—Travoprost—glaucoma	3.33e-05	0.000294	CcSEcCtD
Nilotinib—Nausea—Brimonidine—glaucoma	3.32e-05	0.000293	CcSEcCtD
Nilotinib—Feeling abnormal—Clonidine—glaucoma	3.32e-05	0.000293	CcSEcCtD
Nilotinib—Rash—Brinzolamide—glaucoma	3.31e-05	0.000292	CcSEcCtD
Nilotinib—Vision blurred—Timolol—glaucoma	3.31e-05	0.000292	CcSEcCtD
Nilotinib—Dermatitis—Brinzolamide—glaucoma	3.3e-05	0.000292	CcSEcCtD
Nilotinib—Gastrointestinal pain—Clonidine—glaucoma	3.29e-05	0.000291	CcSEcCtD
Nilotinib—Headache—Brinzolamide—glaucoma	3.28e-05	0.00029	CcSEcCtD
Nilotinib—Hypotension—Betaxolol—glaucoma	3.27e-05	0.000289	CcSEcCtD
Nilotinib—Vomiting—Pilocarpine—glaucoma	3.2e-05	0.000283	CcSEcCtD
Nilotinib—Urticaria—Clonidine—glaucoma	3.2e-05	0.000282	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Betaxolol—glaucoma	3.19e-05	0.000282	CcSEcCtD
Nilotinib—Abdominal pain—Clonidine—glaucoma	3.18e-05	0.000281	CcSEcCtD
Nilotinib—Body temperature increased—Clonidine—glaucoma	3.18e-05	0.000281	CcSEcCtD
Nilotinib—Rash—Pilocarpine—glaucoma	3.18e-05	0.000281	CcSEcCtD
Nilotinib—Dermatitis—Pilocarpine—glaucoma	3.17e-05	0.00028	CcSEcCtD
Nilotinib—Insomnia—Betaxolol—glaucoma	3.17e-05	0.00028	CcSEcCtD
Nilotinib—Nausea—Dorzolamide—glaucoma	3.17e-05	0.00028	CcSEcCtD
Nilotinib—Headache—Pilocarpine—glaucoma	3.16e-05	0.000279	CcSEcCtD
Nilotinib—Nausea—Travoprost—glaucoma	3.15e-05	0.000279	CcSEcCtD
Nilotinib—Vertigo—Timolol—glaucoma	3.15e-05	0.000278	CcSEcCtD
Nilotinib—Paraesthesia—Betaxolol—glaucoma	3.15e-05	0.000278	CcSEcCtD
Nilotinib—Syncope—Timolol—glaucoma	3.15e-05	0.000278	CcSEcCtD
Nilotinib—Dyspnoea—Betaxolol—glaucoma	3.12e-05	0.000276	CcSEcCtD
Nilotinib—Nausea—Brinzolamide—glaucoma	3.11e-05	0.000275	CcSEcCtD
Nilotinib—Palpitations—Timolol—glaucoma	3.1e-05	0.000274	CcSEcCtD
Nilotinib—Dyspepsia—Betaxolol—glaucoma	3.08e-05	0.000272	CcSEcCtD
Nilotinib—Loss of consciousness—Timolol—glaucoma	3.08e-05	0.000272	CcSEcCtD
Nilotinib—Cough—Timolol—glaucoma	3.06e-05	0.00027	CcSEcCtD
Nilotinib—Decreased appetite—Betaxolol—glaucoma	3.05e-05	0.000269	CcSEcCtD
Nilotinib—Hypertension—Timolol—glaucoma	3.03e-05	0.000267	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Betaxolol—glaucoma	3.02e-05	0.000267	CcSEcCtD
Nilotinib—Fatigue—Betaxolol—glaucoma	3.02e-05	0.000267	CcSEcCtD
Nilotinib—Pain—Betaxolol—glaucoma	3e-05	0.000265	CcSEcCtD
Nilotinib—Constipation—Betaxolol—glaucoma	3e-05	0.000265	CcSEcCtD
Nilotinib—Nausea—Pilocarpine—glaucoma	2.99e-05	0.000264	CcSEcCtD
Nilotinib—Chest pain—Timolol—glaucoma	2.99e-05	0.000264	CcSEcCtD
Nilotinib—Myalgia—Timolol—glaucoma	2.99e-05	0.000264	CcSEcCtD
Nilotinib—Arthralgia—Timolol—glaucoma	2.99e-05	0.000264	CcSEcCtD
Nilotinib—Anxiety—Timolol—glaucoma	2.98e-05	0.000263	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Timolol—glaucoma	2.97e-05	0.000262	CcSEcCtD
Nilotinib—Hypersensitivity—Clonidine—glaucoma	2.97e-05	0.000262	CcSEcCtD
Nilotinib—Discomfort—Timolol—glaucoma	2.95e-05	0.000261	CcSEcCtD
Nilotinib—Dry mouth—Timolol—glaucoma	2.92e-05	0.000258	CcSEcCtD
Nilotinib—Asthenia—Clonidine—glaucoma	2.89e-05	0.000255	CcSEcCtD
Nilotinib—Feeling abnormal—Betaxolol—glaucoma	2.89e-05	0.000255	CcSEcCtD
Nilotinib—Confusional state—Timolol—glaucoma	2.89e-05	0.000255	CcSEcCtD
Nilotinib—Oedema—Timolol—glaucoma	2.86e-05	0.000253	CcSEcCtD
Nilotinib—Pruritus—Clonidine—glaucoma	2.85e-05	0.000251	CcSEcCtD
Nilotinib—Infection—Timolol—glaucoma	2.84e-05	0.000251	CcSEcCtD
Nilotinib—Shock—Timolol—glaucoma	2.82e-05	0.000249	CcSEcCtD
Nilotinib—Nervous system disorder—Timolol—glaucoma	2.81e-05	0.000248	CcSEcCtD
Nilotinib—Urticaria—Betaxolol—glaucoma	2.78e-05	0.000246	CcSEcCtD
Nilotinib—Skin disorder—Timolol—glaucoma	2.78e-05	0.000246	CcSEcCtD
Nilotinib—Body temperature increased—Betaxolol—glaucoma	2.77e-05	0.000245	CcSEcCtD
Nilotinib—Hyperhidrosis—Timolol—glaucoma	2.77e-05	0.000244	CcSEcCtD
Nilotinib—Diarrhoea—Clonidine—glaucoma	2.75e-05	0.000243	CcSEcCtD
Nilotinib—Anorexia—Timolol—glaucoma	2.73e-05	0.000241	CcSEcCtD
Nilotinib—Hypotension—Timolol—glaucoma	2.67e-05	0.000236	CcSEcCtD
Nilotinib—Dizziness—Clonidine—glaucoma	2.66e-05	0.000235	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Timolol—glaucoma	2.61e-05	0.00023	CcSEcCtD
Nilotinib—Insomnia—Timolol—glaucoma	2.59e-05	0.000229	CcSEcCtD
Nilotinib—Hypersensitivity—Betaxolol—glaucoma	2.58e-05	0.000228	CcSEcCtD
Nilotinib—Paraesthesia—Timolol—glaucoma	2.57e-05	0.000227	CcSEcCtD
Nilotinib—Vomiting—Clonidine—glaucoma	2.56e-05	0.000226	CcSEcCtD
Nilotinib—Dyspnoea—Timolol—glaucoma	2.55e-05	0.000225	CcSEcCtD
Nilotinib—Rash—Clonidine—glaucoma	2.54e-05	0.000224	CcSEcCtD
Nilotinib—Dermatitis—Clonidine—glaucoma	2.54e-05	0.000224	CcSEcCtD
Nilotinib—Headache—Clonidine—glaucoma	2.52e-05	0.000223	CcSEcCtD
Nilotinib—Dyspepsia—Timolol—glaucoma	2.52e-05	0.000222	CcSEcCtD
Nilotinib—Asthenia—Betaxolol—glaucoma	2.51e-05	0.000222	CcSEcCtD
Nilotinib—Decreased appetite—Timolol—glaucoma	2.49e-05	0.00022	CcSEcCtD
Nilotinib—Pruritus—Betaxolol—glaucoma	2.48e-05	0.000219	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Timolol—glaucoma	2.47e-05	0.000218	CcSEcCtD
Nilotinib—Fatigue—Timolol—glaucoma	2.47e-05	0.000218	CcSEcCtD
Nilotinib—Pain—Timolol—glaucoma	2.45e-05	0.000216	CcSEcCtD
Nilotinib—Diarrhoea—Betaxolol—glaucoma	2.4e-05	0.000212	CcSEcCtD
Nilotinib—Nausea—Clonidine—glaucoma	2.39e-05	0.000211	CcSEcCtD
Nilotinib—Feeling abnormal—Timolol—glaucoma	2.36e-05	0.000208	CcSEcCtD
Nilotinib—Gastrointestinal pain—Timolol—glaucoma	2.34e-05	0.000207	CcSEcCtD
Nilotinib—Dizziness—Betaxolol—glaucoma	2.32e-05	0.000205	CcSEcCtD
Nilotinib—Urticaria—Timolol—glaucoma	2.27e-05	0.000201	CcSEcCtD
Nilotinib—Body temperature increased—Timolol—glaucoma	2.26e-05	0.0002	CcSEcCtD
Nilotinib—Abdominal pain—Timolol—glaucoma	2.26e-05	0.0002	CcSEcCtD
Nilotinib—Vomiting—Betaxolol—glaucoma	2.23e-05	0.000197	CcSEcCtD
Nilotinib—Rash—Betaxolol—glaucoma	2.21e-05	0.000195	CcSEcCtD
Nilotinib—Dermatitis—Betaxolol—glaucoma	2.21e-05	0.000195	CcSEcCtD
Nilotinib—Headache—Betaxolol—glaucoma	2.19e-05	0.000194	CcSEcCtD
Nilotinib—Hypersensitivity—Timolol—glaucoma	2.11e-05	0.000186	CcSEcCtD
Nilotinib—Nausea—Betaxolol—glaucoma	2.08e-05	0.000184	CcSEcCtD
Nilotinib—Asthenia—Timolol—glaucoma	2.05e-05	0.000181	CcSEcCtD
Nilotinib—Pruritus—Timolol—glaucoma	2.03e-05	0.000179	CcSEcCtD
Nilotinib—Diarrhoea—Timolol—glaucoma	1.96e-05	0.000173	CcSEcCtD
Nilotinib—Dizziness—Timolol—glaucoma	1.89e-05	0.000167	CcSEcCtD
Nilotinib—Vomiting—Timolol—glaucoma	1.82e-05	0.000161	CcSEcCtD
Nilotinib—Rash—Timolol—glaucoma	1.8e-05	0.000159	CcSEcCtD
Nilotinib—Dermatitis—Timolol—glaucoma	1.8e-05	0.000159	CcSEcCtD
Nilotinib—Headache—Timolol—glaucoma	1.79e-05	0.000158	CcSEcCtD
Nilotinib—Nausea—Timolol—glaucoma	1.7e-05	0.00015	CcSEcCtD
Nilotinib—MAP2K5—Signaling Pathways—BAD—glaucoma	2.36e-06	2.52e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—EDN1—glaucoma	2.35e-06	2.52e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—BAD—glaucoma	2.35e-06	2.52e-05	CbGpPWpGaD
Nilotinib—CA1—Metabolism—PTGS2—glaucoma	2.34e-06	2.5e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—NGFR—glaucoma	2.33e-06	2.5e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—APOE—glaucoma	2.33e-06	2.49e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—CDKN2B—glaucoma	2.32e-06	2.48e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—TXN—glaucoma	2.31e-06	2.48e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—CAV1—glaucoma	2.31e-06	2.47e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—ABCA1—glaucoma	2.3e-06	2.47e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—CYP1B1—glaucoma	2.3e-06	2.47e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—BAD—glaucoma	2.3e-06	2.46e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—BAD—glaucoma	2.29e-06	2.45e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—C3—glaucoma	2.28e-06	2.44e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—NTRK1—glaucoma	2.27e-06	2.43e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—C3—glaucoma	2.25e-06	2.42e-05	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—CDKN1B—glaucoma	2.25e-06	2.41e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—NOS3—glaucoma	2.25e-06	2.41e-05	CbGpPWpGaD
Nilotinib—CA9—Metabolism—NOS3—glaucoma	2.25e-06	2.41e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—NTRK2—glaucoma	2.23e-06	2.39e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—EDN1—glaucoma	2.22e-06	2.38e-05	CbGpPWpGaD
Nilotinib—LYN—Developmental Biology—TNF—glaucoma	2.22e-06	2.38e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—NTRK1—glaucoma	2.22e-06	2.38e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—NGFR—glaucoma	2.21e-06	2.37e-05	CbGpPWpGaD
Nilotinib—ABL1—Developmental Biology—TNF—glaucoma	2.21e-06	2.37e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—BAD—glaucoma	2.18e-06	2.34e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—C3—glaucoma	2.17e-06	2.33e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—GSTM1—glaucoma	2.17e-06	2.33e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—BAD—glaucoma	2.17e-06	2.32e-05	CbGpPWpGaD
Nilotinib—LCK—Adaptive Immune System—CDKN1B—glaucoma	2.16e-06	2.32e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—NGF—glaucoma	2.16e-06	2.31e-05	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—CDKN1B—glaucoma	2.13e-06	2.28e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—APOE—glaucoma	2.12e-06	2.27e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—GSTT1—glaucoma	2.12e-06	2.27e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism of lipids and lipoproteins—APOE—glaucoma	2.11e-06	2.26e-05	CbGpPWpGaD
Nilotinib—MAPK14—Developmental Biology—TNF—glaucoma	2.1e-06	2.25e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—NTRK1—glaucoma	2.1e-06	2.25e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—CAV1—glaucoma	2.1e-06	2.25e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—APOE—glaucoma	2.1e-06	2.25e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism of lipids and lipoproteins—CAV1—glaucoma	2.09e-06	2.24e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CDKN2B—glaucoma	2.09e-06	2.24e-05	CbGpPWpGaD
Nilotinib—LCK—Hemostasis—VEGFA—glaucoma	2.08e-06	2.23e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—CAV1—glaucoma	2.08e-06	2.23e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—BCL2L1—glaucoma	2.08e-06	2.23e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—PTGS2—glaucoma	2.05e-06	2.2e-05	CbGpPWpGaD
Nilotinib—CA9—Metabolism—PTGS2—glaucoma	2.05e-06	2.2e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—C3—glaucoma	2.05e-06	2.2e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CDKN2B—glaucoma	2.04e-06	2.19e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—NOS3—glaucoma	2.04e-06	2.19e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—NGF—glaucoma	2.04e-06	2.19e-05	CbGpPWpGaD
Nilotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—glaucoma	2.04e-06	2.18e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—TXN—glaucoma	2.02e-06	2.16e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—MTHFR—glaucoma	2.01e-06	2.15e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—EDN1—glaucoma	2e-06	2.15e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—FN1—glaucoma	2e-06	2.14e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—NOS3—glaucoma	1.99e-06	2.14e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—FN1—glaucoma	1.98e-06	2.12e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—BAD—glaucoma	1.97e-06	2.12e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—EDN1—glaucoma	1.96e-06	2.1e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—BAD—glaucoma	1.96e-06	2.1e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—CDKN1B—glaucoma	1.95e-06	2.08e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—C3—glaucoma	1.94e-06	2.08e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CDKN2B—glaucoma	1.94e-06	2.08e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—NOS3—glaucoma	1.93e-06	2.07e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CA1—glaucoma	1.93e-06	2.07e-05	CbGpPWpGaD
Nilotinib—LYN—Hemostasis—TP53—glaucoma	1.92e-06	2.06e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—CDKN1B—glaucoma	1.92e-06	2.06e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—MTHFR—glaucoma	1.92e-06	2.06e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—NGFR—glaucoma	1.91e-06	2.05e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—APOE—glaucoma	1.91e-06	2.05e-05	CbGpPWpGaD
Nilotinib—ABL1—Hemostasis—TP53—glaucoma	1.91e-06	2.05e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—TXN—glaucoma	1.9e-06	2.04e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—NOS3—glaucoma	1.89e-06	2.03e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—CAV1—glaucoma	1.89e-06	2.03e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—BAD—glaucoma	1.88e-06	2.02e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—TXN—glaucoma	1.88e-06	2.02e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—PTGS2—glaucoma	1.87e-06	2e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—APOE—glaucoma	1.87e-06	2e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CTSA—glaucoma	1.87e-06	2e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—EDN1—glaucoma	1.86e-06	1.99e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—CAV1—glaucoma	1.85e-06	1.98e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—GSTM1—glaucoma	1.84e-06	1.97e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—NGF—glaucoma	1.84e-06	1.97e-05	CbGpPWpGaD
Nilotinib—MAPK14—Hemostasis—TP53—glaucoma	1.82e-06	1.95e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—NTRK1—glaucoma	1.82e-06	1.95e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—CDKN1B—glaucoma	1.82e-06	1.95e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—APOE—glaucoma	1.81e-06	1.94e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—NGF—glaucoma	1.8e-06	1.93e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—FN1—glaucoma	1.8e-06	1.93e-05	CbGpPWpGaD
Nilotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—glaucoma	1.8e-06	1.92e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—GSTT1—glaucoma	1.79e-06	1.92e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—CAV1—glaucoma	1.79e-06	1.92e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—APOE—glaucoma	1.79e-06	1.91e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—BAD—glaucoma	1.78e-06	1.91e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—CDKN1B—glaucoma	1.77e-06	1.9e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—PTGS2—glaucoma	1.77e-06	1.9e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—CAV1—glaucoma	1.77e-06	1.9e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CA2—glaucoma	1.76e-06	1.89e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—C3—glaucoma	1.75e-06	1.88e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—NOS3—glaucoma	1.74e-06	1.87e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—BAD—glaucoma	1.74e-06	1.86e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—CDKN1B—glaucoma	1.73e-06	1.85e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—APOE—glaucoma	1.72e-06	1.84e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—C3—glaucoma	1.71e-06	1.84e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—NGF—glaucoma	1.71e-06	1.83e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—FN1—glaucoma	1.71e-06	1.83e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—CAV1—glaucoma	1.7e-06	1.82e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—ABCA1—glaucoma	1.69e-06	1.81e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—CYP1B1—glaucoma	1.69e-06	1.81e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—BAD—glaucoma	1.69e-06	1.81e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—CDKN1B—glaucoma	1.68e-06	1.8e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CDKN2B—glaucoma	1.68e-06	1.8e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—CDKN1B—glaucoma	1.64e-06	1.76e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—CDKN1B—glaucoma	1.64e-06	1.75e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—APOE—glaucoma	1.63e-06	1.75e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—MTHFR—glaucoma	1.63e-06	1.74e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—C3—glaucoma	1.62e-06	1.74e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CAV1—glaucoma	1.61e-06	1.73e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—EDN1—glaucoma	1.61e-06	1.72e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—CDKN1B—glaucoma	1.6e-06	1.72e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—MMP9—glaucoma	1.6e-06	1.71e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—APOE—glaucoma	1.6e-06	1.71e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—PTGS2—glaucoma	1.59e-06	1.71e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—CDKN1B—glaucoma	1.59e-06	1.71e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—NOS3—glaucoma	1.59e-06	1.7e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CAV1—glaucoma	1.58e-06	1.69e-05	CbGpPWpGaD
Nilotinib—LCK—Hemostasis—TP53—glaucoma	1.57e-06	1.69e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—NOS3—glaucoma	1.57e-06	1.69e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—GSTT1—glaucoma	1.56e-06	1.67e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—FN1—glaucoma	1.54e-06	1.65e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—MMP9—glaucoma	1.52e-06	1.63e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—BAD—glaucoma	1.52e-06	1.63e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—CDKN1B—glaucoma	1.52e-06	1.63e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—APOE—glaucoma	1.51e-06	1.62e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—APOE—glaucoma	1.51e-06	1.62e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—CDKN1B—glaucoma	1.51e-06	1.62e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—FN1—glaucoma	1.5e-06	1.61e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—CAV1—glaucoma	1.5e-06	1.61e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CAV1—glaucoma	1.5e-06	1.61e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—BAD—glaucoma	1.49e-06	1.59e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—NGF—glaucoma	1.48e-06	1.58e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—GSTT1—glaucoma	1.47e-06	1.58e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—GSTT1—glaucoma	1.46e-06	1.56e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—glaucoma	1.45e-06	1.55e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—VEGFA—glaucoma	1.44e-06	1.54e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—NOS3—glaucoma	1.43e-06	1.53e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—ABCA1—glaucoma	1.43e-06	1.53e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—CYP1B1—glaucoma	1.43e-06	1.53e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—FN1—glaucoma	1.43e-06	1.53e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—BAD—glaucoma	1.41e-06	1.51e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—C3—glaucoma	1.4e-06	1.51e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—NOS3—glaucoma	1.4e-06	1.5e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—CDKN1B—glaucoma	1.38e-06	1.47e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—VEGFA—glaucoma	1.36e-06	1.46e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—CDKN1B—glaucoma	1.36e-06	1.46e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—NOS3—glaucoma	1.35e-06	1.45e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—GSTM1—glaucoma	1.35e-06	1.45e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—NOS3—glaucoma	1.34e-06	1.43e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—CDKN1B—glaucoma	1.31e-06	1.41e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—APOE—glaucoma	1.31e-06	1.4e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CAV1—glaucoma	1.3e-06	1.39e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—PTGS2—glaucoma	1.28e-06	1.37e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—MMP9—glaucoma	1.27e-06	1.36e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—MMP9—glaucoma	1.26e-06	1.35e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—CYP1B1—glaucoma	1.25e-06	1.33e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—ABCA1—glaucoma	1.25e-06	1.33e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—TXN—glaucoma	1.24e-06	1.33e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—CDKN1B—glaucoma	1.24e-06	1.33e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—FN1—glaucoma	1.23e-06	1.32e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—PTGS2—glaucoma	1.22e-06	1.31e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—NOS3—glaucoma	1.22e-06	1.31e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—BAD—glaucoma	1.22e-06	1.31e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—CDKN1B—glaucoma	1.21e-06	1.3e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—NOS3—glaucoma	1.2e-06	1.28e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—MTHFR—glaucoma	1.19e-06	1.28e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—glaucoma	1.18e-06	1.26e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—CDKN1B—glaucoma	1.17e-06	1.26e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—ABCA1—glaucoma	1.17e-06	1.26e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—CYP1B1—glaucoma	1.17e-06	1.26e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—CYP1B1—glaucoma	1.16e-06	1.25e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—ABCA1—glaucoma	1.16e-06	1.25e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—MMP9—glaucoma	1.15e-06	1.23e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—VEGFA—glaucoma	1.14e-06	1.23e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—GSTM1—glaucoma	1.14e-06	1.22e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—NOS3—glaucoma	1.13e-06	1.22e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—NOS3—glaucoma	1.13e-06	1.21e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—VEGFA—glaucoma	1.13e-06	1.21e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—APOE—glaucoma	1.11e-06	1.19e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—CAV1—glaucoma	1.1e-06	1.18e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—MMP9—glaucoma	1.09e-06	1.16e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—TP53—glaucoma	1.08e-06	1.16e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CDKN1B—glaucoma	1.06e-06	1.13e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—PTGS2—glaucoma	1.04e-06	1.11e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CDKN1B—glaucoma	1.04e-06	1.11e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—VEGFA—glaucoma	1.03e-06	1.11e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—TP53—glaucoma	1.03e-06	1.11e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—MTHFR—glaucoma	1.01e-06	1.08e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—GSTM1—glaucoma	9.95e-07	1.07e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CDKN1B—glaucoma	9.81e-07	1.05e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—NOS3—glaucoma	9.8e-07	1.05e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—MMP9—glaucoma	9.79e-07	1.05e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—VEGFA—glaucoma	9.76e-07	1.05e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—GSTT1—glaucoma	9.63e-07	1.03e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—MMP9—glaucoma	9.59e-07	1.03e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—APOE—glaucoma	9.4e-07	1.01e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—GSTM1—glaucoma	9.38e-07	1.01e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—CAV1—glaucoma	9.31e-07	9.98e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—GSTM1—glaucoma	9.3e-07	9.97e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—MMP9—glaucoma	9.09e-07	9.74e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—MTHFR—glaucoma	8.8e-07	9.43e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—VEGFA—glaucoma	8.79e-07	9.42e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—TP53—glaucoma	8.64e-07	9.26e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—VEGFA—glaucoma	8.61e-07	9.23e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—TP53—glaucoma	8.56e-07	9.17e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CDKN1B—glaucoma	8.49e-07	9.09e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—NOS3—glaucoma	8.32e-07	8.92e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—MTHFR—glaucoma	8.29e-07	8.88e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—MTHFR—glaucoma	8.22e-07	8.81e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—APOE—glaucoma	8.19e-07	8.78e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—VEGFA—glaucoma	8.16e-07	8.75e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—CAV1—glaucoma	8.11e-07	8.7e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—MMP9—glaucoma	7.86e-07	8.42e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—TP53—glaucoma	7.79e-07	8.35e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—APOE—glaucoma	7.72e-07	8.27e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CYP1B1—glaucoma	7.67e-07	8.22e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—ABCA1—glaucoma	7.67e-07	8.22e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—APOE—glaucoma	7.65e-07	8.2e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—CAV1—glaucoma	7.65e-07	8.19e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PTGS2—glaucoma	7.61e-07	8.15e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—CAV1—glaucoma	7.58e-07	8.12e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—TP53—glaucoma	7.38e-07	7.9e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—VEGFA—glaucoma	7.06e-07	7.56e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—NOS3—glaucoma	7.04e-07	7.55e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—TP53—glaucoma	6.64e-07	7.12e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—TP53—glaucoma	6.51e-07	6.97e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PTGS2—glaucoma	6.44e-07	6.9e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—TP53—glaucoma	6.17e-07	6.61e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—NOS3—glaucoma	6.14e-07	6.58e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—GSTM1—glaucoma	6.13e-07	6.57e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—NOS3—glaucoma	5.78e-07	6.2e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—NOS3—glaucoma	5.73e-07	6.14e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PTGS2—glaucoma	5.61e-07	6.01e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—MTHFR—glaucoma	5.42e-07	5.81e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—TP53—glaucoma	5.33e-07	5.71e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PTGS2—glaucoma	5.29e-07	5.67e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PTGS2—glaucoma	5.24e-07	5.62e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—APOE—glaucoma	5.05e-07	5.41e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CAV1—glaucoma	5e-07	5.36e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—NOS3—glaucoma	3.78e-07	4.05e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PTGS2—glaucoma	3.46e-07	3.71e-06	CbGpPWpGaD
